Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
Location status: Recruiting
NCT Number: NCT06313567
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
Interested in participating?
Request Info18 year–80 year
All sexes
Interventional
Phase 3
Shanghai, Shanghai Municipality, 200000, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
500 mg/m2 body surface area twice daily for 1 year; metronomic capecitabine group
observation
Time frame: 3-year
DFS
Time frame: 3-year
OS
Time frame: 1-year
Complications such as Nausea, vomiting, myelosuppression and Liver or kidney function disorder
Contact information is provided by the study sponsor or research team.
Fudan University
Other
Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03190941
Colon Cancer, Colonic Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT04284943
Diabetes Mellitus, Diabetes Mellitus, Type 2
Seoul, South Korea
View Trial DetailsNCT07227168
Cervical Cancer, Colonic Diseases
Denver, Colorado, United States
View Trial DetailsNCT07705334
Adenoma, Advanced or Metastatic Solid Tumors
Denver, Colorado, United States
View Trial Details